These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33965136)

  • 1. Response.
    Narain S; Stefanov DG; Marder G; Kaplan B; Hajizadeh N
    Chest; 2021 May; 159(5):2109-2110. PubMed ID: 33965136
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease.
    González-Castro A; Cuenca Fito E; Fernandez A; Escudero Acha P; Rodríguez Borregán JC; Peñasco Y
    Med Intensiva (Engl Ed); 2022 May; 46(5):285-287. PubMed ID: 35256321
    [No Abstract]   [Full Text] [Related]  

  • 3. Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One.
    Kow CS; Hasan SS
    Chest; 2021 May; 159(5):2108-2109. PubMed ID: 33965134
    [No Abstract]   [Full Text] [Related]  

  • 4. Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Anti-inflammatory Therapy for Severe Coronavirus Disease (COVID).
    Martínez-Urbistondo D; Costa Segovia R; Suárez Del Villar Carrero R; Risco Risco C; Villares Fernández P
    Clin Infect Dis; 2021 May; 72(9):1682-1683. PubMed ID: 32621739
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
    Chen XJC; Altshuler D; Spiegler P; Brosnahan SB
    Ann Pharmacother; 2022 Apr; 56(4):507-508. PubMed ID: 34330173
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
    Bissell BD; Mefford B; Donaldson JC
    Ann Pharmacother; 2022 Apr; 56(4):505-506. PubMed ID: 34330160
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19, steroids and other immunomodulators: The jigsaw is not complete.
    Rello J; Waterer GW; Bourdiol A; Roquilly A
    Anaesth Crit Care Pain Med; 2020 Dec; 39(6):699-701. PubMed ID: 33115684
    [No Abstract]   [Full Text] [Related]  

  • 8. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.
    Yurttutan S; Gullu UU; Ipek S
    Intern Emerg Med; 2021 Jun; 16(4):1101-1103. PubMed ID: 33598871
    [No Abstract]   [Full Text] [Related]  

  • 9. Myopathy associated with severe SARS-CoV-2 infection.
    Abenza Abildúa MJ; Ramírez Prieto MT; Moreno Zabaleta R; Algarra Lucas C; Pérez López C
    Neurologia (Engl Ed); 2020; 35(9):706-708. PubMed ID: 32893072
    [No Abstract]   [Full Text] [Related]  

  • 10. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.
    Aomar-Millán IF; Salvatierra J; Hernández-Quero J
    Intern Emerg Med; 2021 Jun; 16(4):1105-1106. PubMed ID: 33694056
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient.
    Sagnelli C; Gentile V; Tirri R; Macera M; Cappabianca S; Ciccia F; Coppola N;
    J Infect; 2020 Dec; 81(6):979-997. PubMed ID: 32474034
    [No Abstract]   [Full Text] [Related]  

  • 12. [Sotrovimab in controlling SARS-CoV-2 infection].
    Płusa T
    Pol Merkur Lekarski; 2022 Feb; 50(295):48-50. PubMed ID: 35278299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.
    Conte WL
    Mult Scler Relat Disord; 2020 Sep; 44():102315. PubMed ID: 32593144
    [No Abstract]   [Full Text] [Related]  

  • 14. Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019.
    Koeckerling D; Barker J
    J Infect Dis; 2021 Sep; 224(6):934-937. PubMed ID: 34157110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to "Tocilizumab therapy and COVID-19".
    Bhargava P
    J Osteopath Med; 2021 Sep; 121(11):867-868. PubMed ID: 34492174
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort study.
    Kumar V J; Banu S; Sasikala M; Parsa KVL; Sowpati DT; Yadav R; Tallapaka KB; Siva AB; Vishnubhotla R; Rao GV; Reddy DN
    J Intern Med; 2022 Mar; 291(3):380-383. PubMed ID: 34719811
    [No Abstract]   [Full Text] [Related]  

  • 17. Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.
    Shabani M; Shokouhi S; Moradi O; Saffaei A; Sahraei Z
    J Med Virol; 2021 Jan; 93(1):69-70. PubMed ID: 32492210
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
    Saultier P; Ninove L; Szepetowski S; Veneziano M; Visentin S; Barlogis V; Saba Villarroel PM; Amroun A; Loosveld M; de Lamballerie X; Chambost H
    Br J Haematol; 2022 Jan; 196(1):e1-e3. PubMed ID: 34337739
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 20. Response.
    Price CC; Altice FL; Azar MM; McManus D; Gleeson SE; Britto CJ; Azmy V; Kaman K; Davis M; Chupp G; Bucala R; Kaminski N; Topal JE; Dela Cruz C; Malinis M
    Chest; 2021 May; 159(5):2116-2117. PubMed ID: 33965143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.